Filters








130 Hits in 2.4 sec

Functional foods for dyslipidaemia and cardiovascular risk prevention

Cesare R. Sirtori, Claudio Galli, James W. Anderson, Elena Sirtori, Anna Arnoldi
2009 Nutrition research reviews  
Sirtori CR, Paoletti R, Mancini M, et al. (1997) n-3 Fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance.  ...  Sirtori CR & Galli C (2002) n-3 Fatty acids and diabetes. Biomed Pharmacother 56, 397-406. 49.  ... 
doi:10.1017/s0954422409990187 pmid:20003590 fatcat:ztxpd3rzyrcnlcuewpczxezrfu

PCSK9 antagonists and inflammation

Massimiliano Ruscica, Nicola Ferri, Alberto Corsini, Cesare R. Sirtori
2018 Atherosclerosis  
doi:10.1016/j.atherosclerosis.2017.10.022 pmid:29102656 fatcat:nb2oewhle5bgzc4jahsun3fwhq

Obesity and thrombotic risk

Susanna Colli, Cesare R. Sirtori
2010 British Journal of Nutrition  
Professor Susanna Colli Professor Cesare R.  ...  Sirtori Department of Pharmacological Sciences Università degli Studi di Milano Milan Italy email susanna.colli@unimi.it https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114510002849  ... 
doi:10.1017/s0007114510002849 pmid:21126383 fatcat:2xvlscffgzedfefo27v4w6qaee

Increased platelet sensitivity and thromboxane B2formation in type-II hyperlipoproteinaemic patients

ELENA TREMOLI, PAOLA MADERNA, SUSANNA COLLI, GABRIELE MORAZZONI, MARINA SIRTORI, CESARE R. SIRTORI
1984 European Journal of Clinical Investigation  
& CESARE R.  ...  SIRTORI, E.  ... 
doi:10.1111/j.1365-2362.1984.tb01191.x pmid:6437830 fatcat:tdp65d345rhdhdlx65qwapukmy

PCSK9 inhibition and inflammation: A narrative review

Massimiliano Ruscica, Lale Tokgözoğlu, Alberto Corsini, Cesare R. Sirtori
2019 Atherosclerosis  
These data 4 U N C O R R E C T E D P R O O F M. Ruscica et al.  ...  Clinical study hs-CRP (mg/L) U N C O R R E C T E D P R O O F M.Ruscica et al. Atherosclerosis xxx (xxxx) xxx-xxx  ... 
doi:10.1016/j.atherosclerosis.2019.07.015 pmid:31404822 fatcat:2qbvfn6dvvajpcnfdq336gauyu

HDL and the progression of atherosclerosis: new insights

Cesare R. Sirtori
2006 European Heart Journal, Supplement  
Aims Lowering low-density lipoprotein (LDL) cholesterol or raising high-density lipoprotein (HDL) cholesterol can result in significant cardiovascular benefit, both in terms of reduction of events and also, to a variable extent, of atheromatous lesions. LDL and HDL have opposite roles in body cholesterol regulation and, both reduced deposition (LDL reduction) and increased removal (raised HDL) can improve vascular disease. Very recently, studies using recombinant apolipoprotein AI liposomes (in
more » ... particular with the mutant apo AI Milano ) have shown that direct infusion can effectively remove cellular cholesterol and dramatically reduce established atheromatous plaques in animals and in coronary patients. It has thus become of growing interest, the possibility of raising HDL by pharmacological treatments. This review will attempt to investigate existing and novel methodologies for HDL raising. Methods and results HDL raising can be achieved by using drugs active on the peroxisome proliferator activated receptor a (PPAR a) system, particularly using fibrates or n-3 fatty acids and, possibly more effectively, by using nicotinic acid. The activity of this agent has been traditionally linked to a reduced free fatty acid (FFA) mobilization from adipose tissue. More recently, it has been noted that nicotinic acid can activate the PPAR system, by stimulating all three PPAR isoforms (a, g, d). This mode of action seems to more effectively explain the striking HDL-raising properties of the drug. Conclusions Newly discovered mechanisms of nicotinic acid can explain, on the one hand, reduced atherosclerosis progression in secondary prevention patients treated with statins and, on the other hand, improved body cholesterol mobilization, effectively reducing cholesterol pool sizes.
doi:10.1093/eurheartj/sul034 fatcat:rufod7gs45bu5d5gmgtc6vdbqu

Dietary animal proteins and cholesterol metabolism in rabbits

Maria R. Lovati, Clive E. West, Cesare R. Sirtori, Anton C. Beynen
1990 British Journal of Nutrition  
The liver responds by decreasing the number of low-density-lipoprotein (LDL) receptors (Sirtori et ul. 1984) .  ...  R E S U L T S At the end of the pre-experimental period, body-weights of the rabbits fed on the soya-bean protein diets averaged 2527 (SE 19) g (n 56) and during the experimental period of 29 d, the growth  ... 
doi:10.1079/bjn19900047 pmid:2223748 fatcat:j2eqs6ed2fgipafndicc33x7km

Present therapeutic role of cholesteryl ester transfer protein inhibitors

Nicola Ferri, Alberto Corsini, Cesare R. Sirtori, Massimiliano Ruscica
2018 Pharmacological Research  
., Present therapeutic role of cholesteryl ester transfer protein inhibitors, Pharmacol Res (2017), https://doi.REVEAL trial 23 a b s t r a c t Therapeutic interventions aimed at increasing high-density  ...  Michelagnoli, R. Longhi, G. Gianfranceschi, F. Pazzucconi, L. 961 Calabresi, C.R. Sirtori, G.  ...  Ther. 20 (2015) 483-489. 970 [45] R. Krishna, A. Garg, D. Panebianco, J. Cote, A.J. Bergman, P. Van Hoydonck, T. 971 Laethem, K. Van Dyck, J. Chen, C. Chavez-Eng, L. Archer, R. Lutz, D.  ... 
doi:10.1016/j.phrs.2017.12.028 pmid:29287689 fatcat:37inxczf6fd3rojb5xnkao73lq

Bococizumab for the treatment of hypercholesterolaemia

Nicola Ferri, Alberto Corsini, Cesare R. Sirtori, Massimiliano Ruscica
2017 Expert Opinion on Biological Therapy  
Ridker PM, Amarenco P, Brunell R, et al.  ...  J16 completely blocks the human and mouse PCSK9 binding to the LDL-R [34] .  ... 
doi:10.1080/14712598.2017.1279602 pmid:28060539 fatcat:45vl5k2wq5fmjhc3iovc25le4u

Clinical approach to the inflammatory etiology of cardiovascular diseases

Massimiliano Ruscica, Alberto Corsini, Nicola Ferri, Maciej Banach, Cesare R. Sirtori
2020 Pharmacological Research  
n a l P r e -p r o o f  ...  n a l P r e -p r o o f disorders.  ... 
doi:10.1016/j.phrs.2020.104916 pmid:32445957 pmcid:PMC7238995 fatcat:exojwwgifjegzaed6cvprhbui4

Lipid Lowering Drugs: Present Status and Future Developments

Massimiliano Ruscica, Nicola Ferri, Raul D. Santos, Cesare R. Sirtori, Alberto Corsini
2021 Current Atherosclerosis Reports  
These very positive findings have led to the planning of the PROMINENT (Pemafibrate to R ed uc e Ca r d i o va s cu l a r O u t co m e s b y R e du cin g Triglycerides in Patients with Diabetes) trial  ...  Omega-3 T h e l a t e s t d e v e l o p m e n t i n t h e t r e a t m e n t i n hypertriglyceridemias has been the unexpected CV effectiveness of FA of the n-3 series (i.e., with multiple double bonds,  ... 
doi:10.1007/s11883-021-00918-3 pmid:33694108 pmcid:PMC7946696 fatcat:ewueuitlsrcpveta3yldlxefxi

Status and potential clinical value of a transthoracic evaluation of the coronary arteries

Fabien Labombarda, Samuela Castelnuovo, Dionysis Goularas, Cesare R. Sirtori
2015 Cardiovascular Ultrasound  
The growing need for coronary evaluation has raised interest in non-radioactive, non-invasive monitoring systems. In particular, radiation exposure during coronary investigations has been shown to be a possible cause of an enhanced risk of secondary tumors. Literature search has indicated that transthoracic echocardiography (TTE) has been widely applied to coronary arteries up to 2003, following which the lack of adequate equipment and the increased availability of invasive diagnostics, has
more » ... ced interest in this low cost, low-risk technology. The more recent availability of newer, more sensitive machines, allows evaluation of a larger number of arterial trees, including the aorta in newborns, the prenatal aortic intima-media thickness, as well as the detection of coronary artery anomalies in the adult. Improved technology for this highly operator sensitive technique may thus predict a possible evolution toward the clinical diagnostics of coronary disease and, eventually, also of the progression/ regression of disease. We sought to evaluate the present status of this seldom quoted non-invasive technology.
doi:10.1186/s12947-016-0048-5 pmid:26787070 pmcid:PMC4717568 fatcat:na47jmmxefbxfhnvmh2ytcj7si

Recent advances in synthetic pharmacotherapies for dyslipidaemias

Cesare R Sirtori, Shizuya Yamashita, Maria Francesca Greco, Alberto Corsini, Gerald F Watts, Massimiliano Ruscica
2019 European Journal of Preventive Cardiology  
70 mg/dL on a guideline-based statin regimen. 38, 39 Sirtori et al.  ...  Key secondary endpoints were also Sirtori et al. reduced by 26% with a NNT of 28 (Table 2) .  ... 
doi:10.1177/2047487319845314 pmid:31060364 fatcat:za5iypoi3ra4zi7dlomee7i7py

Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases

Paolo Magni, Chiara Macchi, Cesare R. Sirtori, Massimiliano Marco Corsi Romanelli
2016 Clinical Chemistry and Laboratory Medicine  
AbstractClear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC
more » ... vels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.
doi:10.1515/cclm-2015-0953 pmid:26863345 fatcat:gtsvfdf2szebvhqqozjebownie

The unexpected roles of extracellular ADP and P2Y13 receptor in reverse cholesterol transport

Jean-Marie Boeynaems, Cesare R. Sirtori
2010 Purinergic Signalling Purinergic Signalling  
doi:10.1007/s11302-010-9211-x pmid:21437006 pmcid:PMC3033499 fatcat:d5umch6zlvetldlmoc4hzfemva
« Previous Showing results 1 — 15 out of 130 results